HYPE3HYPERA S.A.Company Data · 2T26updated 2026-08-24
1 Overview 4T10 — 2T26 · 63 quarters
HYPERA S.A.
HYPE3Farmacêutico e Higiene

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

SectorFarmacêutico e Higiene
Company HeadquartersSão Paulo, SP
Full Time Employees10.564
CEOMr. Breno Toledo Pires de Oliveira
Listing SegmentNovo Mercado
Foundation2001
Customer Rating
Employee Rating
Estrutura Acionária
43%Free Float
João Alves De Queiroz Filho26%
Votorantim S.A.16%
Maiorem S.A. de C.V.13%
Negotio Magni S.A De C.V1%
Alvaro Stainfeld Link0%
Free Float43%
Valuation
PriceR$ 21,17
Shares Outstanding703.992
Market Capitalization14.904
( - ) Cash & Equivalents1.579
( + ) Total Debt7.463
( = ) Enterprise Value20.788
P/E8,6x
EV / EBITDA7,3x
R$ 21,17
Adj close · daily
▲ +2,1%
Income Statement
Revenue8.819
EBITDA2.846
EBIT2.515
Net Income1.743
SG&A %(32,9%)
Balance Sheet
Assets25.353
Cash1.579
Total Debt7.463
Net Debt5.884
Fixed Assets16.572
Working Capital1.445
Equity14.431
Invested Capital & Reinvestment
Invested Capital Turnover0,44x
Marginal IC Turnover1,07x
Reinvestment % NOPAT11,9%
Working Capital Turnover6,07x
Cash Conv. Cycle228,8
Fixed Assets Turnover0,54x
D&A % Fixed Assets2,0%
Capex % Revenue7,2%
13,2 %
RoIC · LTM
RoIC (LTM)
Margins & Returns
Revenue Growth32,4%
Gross Margin61,2%
EBITDA Margin32,3%
Net Income Margin19,8%
Effective Tax Rate(5,3%)
Operating Leverage4,89x
RoIC13,2%
RoE13,1%
Capital Structure
Current Ratio1,86x
Financial Leverage1,76x
Asset Turnover0,35x
Net Debt / EBITDA2,07x
Net Debt & Lease / EBITDA2,07x
Cash Flow
CFO Conversion101,3%
FCFF Yield9,9%
FCFE Yield5,1%
Payout Ratio43,0%
Dividend Yield4,7%
Interest % FCFF(0,8%)
Latest CVM filings
  • 2026-08-07reported 2T26
  • 2026-04-28reported 1T26
  • 2026-03-12reported 4T25
  • 2025-10-28reported 3T25
  • 2025-08-06reported 2T25
  • 2025-04-23reported 1T25